{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-151011","form_type":"8-K","ticker":"DNTH","cik":"0001690585","company_name":"Dianthus Therapeutics, Inc. /DE/","filed_at":"2022-05-16T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.852857+00:00","generated_at":"2026-06-25T15:03:08.937938+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Magenta Q1 net loss $23M; MGTA-117 shows target binding and rapid clearance at lowest dose","bullets":["Net loss of $23.0M for Q1 2022 vs. $17.5M in Q1 2021; R&D expenses rose to $16.5M from $11.7M.","Cash, equivalents and marketable securities $156.6M as of Mar 31, 2022; expected to fund operations into Q2 2024.","Phase 1/2 MGTA-117 Cohort 1 data: target binding on CD117+ cells, rapid drug clearance within 48 hours, no serious drug-related AEs; dose escalation to Cohort 2 (0.04 mg/kg) underway.","One patient with low blast burden showed ~83% reduction of bone marrow blasts at day 14; supports planned transition to transplant-eligible AML patients.","IND-enabling studies for CD45-ADC ongoing; key toxicology results expected 2H 2022. MGTA-145 sickle cell trial startup progressing; initial data expected 2H 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-151011","json":"https://secwatch.observer/filing/0001193125-22-151011.json","markdown":"https://secwatch.observer/filing/0001193125-22-151011.md","text":"https://secwatch.observer/filing/0001193125-22-151011.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1690585/000119312522151011/0001193125-22-151011-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1690585/000119312522151011/d264834d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T15:03:08.937938+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}